Back to Current Sarcoma Research

ASSG Endorsed Clinical Study

ASSG01-08 SUNXRT

Title A phase Ib/II study of sunitinib in combination with neoadjuvant radiation in patients with resectable soft-tissue sarcoma
Objective To determine the maximum dose of sunitinib at which the combination of sunitinib and radiotherapy pre-operatively is safe and tolerable
Type Treatment
Population Soft tissue sarcoma
Treatment First line
Phase Ib / II
Drug / Intervention Sunitinib + Radiotherapy
Sponsor Peter MacCallum Cancer Centre
Funding Source Pfizer
Target accrual 26
Expected Completion 2015
Participating Sites Peter MacCallum Cancer Centre, Victoria, Australia
Recruitment Status Closed
Numbers Accrued 7
Publications and Presentations Lewin, J et al. “A Phase Ib/II Translational Study of Sunitinib with Neoadjuvant Radiotherapy in Soft-Tissue Sarcoma.” British Journal of Cancer 111.12 (2014): 2254–2261. PMC. Web. 2 Feb. 2016.
 
Principal Investigator Associate Professor David Thomas
Contact for Further Information Ania Matera - Clinical Trial Manager
Contact Phone Number +61 3 9656 3661
ania.matera@petermac.org
Last update 01-Aug-2017 02:54 PM 

 

biospecimen
Clinical  Data
Contact ASSG